F1 antigenaemia in bubonic plague patients, a marker of gravity and efficacy of therapy.
Chanteau
S
S
Institut Pasteur, Antananarivo, Madagascar. chanteau@pasteur.pasteur.mg
Rabarijaona
L
L
O'Brien
T
T
Rahalison
L
L
Hager
J
J
Boisier
P
P
Burans
J
J
Rasolomaharo
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000097:blood*; D001426:Bacterial Proteins / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D006801:Humans; D008270:Madagascar / Q000453:epidemiology; D010930:Plague / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D013307:Streptomycin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015010:Yersinia pestis / Q000276:immunology* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D015415:Biomarkers; C086725:caf1 protein, Yersinia pestis; D014295:Trimethoprim; D013420:Sulfamethoxazole; D013307:Streptomycin